Herceptin & Roche in India: The battle for life-saving treatment (B)
This case series looks at the actions taken by NGOs, local campaigners and the Indian government, against Roche over its patent for a breast cancer drug “Trastuzumab”, otherwise known as “Herceptin”, Herceptin was an expensive but highly effective treatment for some types of breast cancer and campaigners were vocal in arguing that in emerging markets, such as India, it was beyond the means of the majority of the population. Case B covers the period and actions from January 2013 to mid-2014. Sensing that it would not receive a renewal of its patent protection from the Indian government, in August 2013, Roche decided not to pursue its patent in India. The government fast-tracked local companies to produce biosimilars. In January 2014, the local biosimilar was launched onto the marketplace but it was only 25% less expensive than Herceptin. In an unusual twist, a month later, the Delhi High Court granted Roche an injunction against the generic manufacturers comparing their products to Herceptin in marketing campaigns.
This case series looks to understand how NGOs and local campaigners can affect a company’s ability to market its products or operate in emerging markets.
Roche, Healthcare, Pharmaceuticals
2013-2014
Cranfield University
Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]
Harvard Business School Publishing
60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]
NUCB Business School
1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
The “tragedy of the horizon” captures the gap between long-horizon climate damages and the shorter horizons of corporate decision-making. We provide a contracting account of this idea using a deliberately standard CARA-normal moral-hazard model. U...
Business model innovation (BMI) is critical for firms' long-term survival under environmental dynamism and depends heavily on CEOs' cognition. While Socioemotional Wealth (SEW) explains why family CEOs may resist or engage in BMI, it largely assum...
Over the past years profound changes in the public sentiment and policy environment suggest the beginning of a new era with reversal attitudes towards globalization. Deglobalization which is commonly defined as the process of decreasing interdepen...
in Economic Letters September 2026, vol. 268, 113154, https://doi.org/10.1016/j.econlet.2026.113154
Research Information & Knowledge Hub for additional information on IMD publications
in Long Range Planning August 2026, vol. 59, no. 4, 102656, https://doi.org/10.1016/j.lrp.2026.102656
Research Information & Knowledge Hub for additional information on IMD publications
in Technovation August 2026, vol. 156, 103640, https://doi.org/10.1016/j.technovation.2026.103640
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD
Research Information & Knowledge Hub for additional information on IMD publications